Pricing Log in Create free account
Friday 6 November 2026 Export LNTH’s income statement to Excel — free account

Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.

Revenue
+1.54%
EPS
−17.1%
Free cash flow
+7.71%
Total debt
+0.52%

Quarter to September 2026, against a year earlier

100.54 0.16 −0.16%
Market cap
$6.6B
P/E
24.3×
Fwd P/E
21.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Lantheus Holdings, Inc. 10-K filed Feb 26, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 8:00 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 26, 2025: 45 added · 35 removed · 119 modified; 5 with only figures updated; 1 moved without change

  1. Modified · Overview

    We are the leading radiopharmaceutical-focused company, delivering life-changing science committed to enableenabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products ininto three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our leading Radiopharmaceutical Oncology products helpproduct helps healthcare professionals (“HCPs”) Find, Fight and Follow cancer. Our leading Precision Diagnostic products assist HCPs to Find and Follow diseases, with a focus in cardiology. Our Strategic Partnerships include biomarkers and digital solutions in support of our partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically, and contract development and manufacturing organization (“CDMO”) revenue generated by Evergreen.